Angiogenesis in the treatment of non-small cell lung cancer

Proceedings of the American Thoracic Society

Volumn 6, Issue 2, 2009, Pages 206-217

  Horn, Leora ^a   Sandler, Alan B ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Angiogenesis; Oral multikinase inhibitors; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MOTESANIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TYROSINE KINASE RECEPTOR; VANDETANIB; VASCULOTROPIN RECEPTOR; XL 647;

ABDOMINAL BLEEDING; ABDOMINAL PAIN; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASTHENIA; ATAXIA; BLEEDING; BRAIN ATHEROSCLEROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONVULSION; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSGEUSIA; DYSPHONIA; DYSPNEA; EMBOLISM; EPISTAXIS; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GALLBLADDER DISEASE; GALLBLADDER ENLARGEMENT; GASTROINTESTINAL SYMPTOM; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; KERATOACANTHOMA; LETHARGY; LEUKOENCEPHALOPATHY; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PNEUMONIA; PNEUMOTHORAX; PROTEINURIA; QT PROLONGATION; RASH; RESPIRATORY FAILURE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOEMOLISM; THROMBOSIS; VASCULITIS; VOMITING;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349189877     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200807-066LC     Document Type: Conference Paper

References (107)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
6. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312:1171-1175.
7. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15:102-111.
8. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60:4959-4967.
9. Macchiarini P, Fontanini G, Dulmet E, de Montpreville V, Chapelier AR, Cerrina J, Ladurie FL, Dartevelle PG. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994;57:1534-1539.
10. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
11. Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine S, Angeletti CA, Harris AL, Bevilacqua G. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177:57-63.
12. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-886.
13. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-2049.
14. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-1014.
15. Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-68.
16. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-563.
17. Fontanini G, Vignati S, Boldrini L, Chine S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G. Vascular endothelial growth factor is associated with neovascularization and influences progression of non- small cell lung carcinoma. Clin Cancer Res 1997;3:861-865.
18. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
19. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothe- lial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
20. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevaci- zumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
22. Dowlati A, Gray R, Johnson DH, Schiller JH, Brahmer J, Sandler AB. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel {+/-} bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2006;24:7027.
23. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
24. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
25. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsch V, Leighl N, Mezger J, Archer V, Reck M, et al.: BO17704 Study Group. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract]. ASCO Meeting Abstracts 2007;25: LBA7514.
26. Reynolds C, Barrera D, Vu DQ, Jotte R, Spira AI, Weissman CH, Boehm KA, Ilegbodu D, Pritchard S, Asmar L. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non- squamous non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:7610.
27. William WN Jr, Kies MS, Fossella FV, Gladish G, Heymach JV, Glisson BS, Tse WH, Liu D, Herbst RS, Lippman SM. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:18098.
28. Ferrer N, Paredes A, Munoz-Langa JM, Mendez M, Cobo M, de-Portugal T, Giner V, Garcia S, Gallego R, Torrego J. Bevacizu- mab in combination with cisplatin and docetaxel as first line treatment of patients (pts) with advanced or metastatic, non squamous, non-small- cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2008;26: 19109.
29. Dalsania CJ, Hageboutros A, Harris E, Krieger K, Vora C, Stevenson J. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer [abstract]. ASCO Meeting Abstracts 2007;25:18163.
30. Patel JD, Hensing TA, Villafor V, Hart E, Bonomi P. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): preliminary results [abstract]. ASCO Meeting Abstracts 2007;25:7601.
31. Heist RS, Fidias P, Huberman M, Temel J, Sequist L, Lynch TJ. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously- treated advanced non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:7700.
32. Waples JM, Auerbach M, Boccia R, Wiggans RG, Steis R; International Oncology Network. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer [abstracts]. ASCO Meeting Abstracts 2007;25:18025.
33. Davila E, Lilenbaum R, Raez L, Seigel L, Tseng J, Graham P. Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC) [abstracts]. ASCO Meeting Abstracts 2006;24:17009.
34. Kraut MJ. Phase II study of gemcitabine and carboplatin plus bevacizumab for stage III/IV non-small cell lung cancer: preliminary safety data [abstract]. ASCO Meeting Abstracts 2006;24:17091.
35. Rizvi NA, Rusch V, Zhao B, Senturk E, Schwartz L, Fury M, Downey R, Rizk N, Krug L, Kris MG. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer [abstract]. ASCO Meeting Abstracts 2007;25:18045.
36. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KLA, Stella PJ, Rowland KM Jr, Schild SR, Zinner R. A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): an NCCTG and SWOG study [abstract]. ASCO Meeting Abstracts 2008;26:8080.
37. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
38. Akerley WL, Langer CJ, Oh Y, Strickland DK, Royer SJ, Xia Q, Mu Y, Huang J, Socinski MA. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer [abstract]. ASCO Meeting Abstracts 2008;26:8043.
39. Dansin E, Mezger J, Isla D, Barlesi F, Bearz A, Lopez PG, Laskin JJ, Pavlakis N, Thatcher N, Crino L. Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL) [abstract]. ASCO Meeting Abstracts 2008;26:8085.
40. Griesinger F, Laskin JJ, Pavlakis N; MO19390 Study Group. Safety of firstline bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) [abstract]. ASCO Meeting Abstracts 2008;26:8049.
41. Lynch TJ, Brahmer J, Fischbach N, Garst J, Kumar P, Spigel DR, Teng S, Vidaver R, Wang L, Navarro W; ARIES Investigators. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract]. ASCO Meeting Abstracts 2008;26:8077.
42. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
43. Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 2006;12:4421s-4425s.
44. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1 epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23: 2544-2555.
45. Salmon JS, Sandler A, Billheimer D, Herbst RS, Tran HT, Tsao A, Dang TP. MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2005;23:7022.
46. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25: 4743-4750.
47. Polikoff J, Hainsworth JD, Fehrenbacher L, Royer-Joo S, Mu Y, Strickland DK, Miller VA. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS [abstract]. ASCO Meeting Abstracts 2008;26:8079.
48. Groen HJ, Smit EF, Dingemans A. A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:7625.
49. Faoro L, Cohen EE, Govindan R, Kozloff MF, Hoffman PC, Maitland ML, Verel K, Szeto L, Salgia R, Vokes EE. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2008;26:19130.
50. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-6392S.
51. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
52. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis,
53. and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169:1875-1885.
54. Carter C, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X. Sorafenib is efficacious and tolerated in combination with cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007;59:183-195.
55. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-2257.
56. Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008;99:1492-1498.
57. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861.
58. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract]. ASCO Meeting Abstracts 2006;24:7002.
59. Liu B, Barrett T, Choyke P, Maynard K, Wright J, Kummar S, Murgo A, Doroshow J, Gutierrez M; NCI Bay 43-9006 Working Group. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2006;24:17119.
60. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo- controlled study in renal cancer. Am J Clin Oncol 2007;30:220-227.
61. Gutierrez M, Kummar S, Allen D, Turkbey B, Choyke P, Wright J, Kurkjian C, Giaccone G, Doroshow J, Murgo A. A phase II study of multikinase inhibitor sorafenib in patients with relapse non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2008;26: 19084.
62. Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM Jr, Jett JR, Mandrekar SJ, Schild SE. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study [abstract]. ASCO Meeting Abstracts 2007;25:7547.
63. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501 [abstract]. ASCO Meeting Abstracts 2008;26:8014.
64. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13:2684-2691.
65. Schiller JH, Flaherty KT, Redlinger M, Binger K, Eun J, Petrenciuc O, O'Dwyer P. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis [abstract]. ASCO Meeting Abstracts 2006;24:7194.
66. Scagliotti G, VonPawelJ, Reck M, CupitL, CihonF, DiMatteo S, O'Leary J, Hanna N. Phase III trial comparing carboplatin and paclitaxel with or without sorafenib in chemonaive patients with stage IIIB (with effusion) or IV non-small cell lung cancer. First IASLC-ESMO European Lung Cancer Conference 2008; Geneva, April 23-26, 2008:48.
67. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
68. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62: 4645-4655.
69. Ciardiello F, Bianco R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepider- mal growth factor receptor therapy. Clin Cancer Res 2004;10:784-793.
70. Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1:1002-1009.
71. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16: 1391-1397.
72. Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, et al. A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3:386-393.
73. Natale RB, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A, Germonpre P, Stockman P, Kennedy S, Ranson M. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two- part, double-blind, randomized phase II trial [abstract]. ASCO Meeting Abstracts 2006;24:7000.
74. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Belani CP, Bodrogi I, Gadgeel S, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25: 4270-4277.
75. Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and pacli- taxel, as 1st-line treatment in patients with NSCLC [abstract]. ASCO Meeting Abstracts 2005;23:7102.
76. Heymach J, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt W, Herbst RS, Krebs A, Langmuir P, Johnson BE. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:7544.
77. Heymach JV, Hanrahan EO, Mann H, Langmuir P, Natale RB, Johnson BE, Herbst RS, Ryan AJ. ASCO Meeting Abstracts 2008; 26:8009.
78. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:1007-1021. (viii).
79. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005;23:3536-3544.
80. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007; 5:203-220.
81. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478.
82. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007;8:15-27.
83. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
84. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006;5:1280-1289.
85. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN. Gillenwater HH, Pallares C, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656.
86. Brahmer JR, Govindan R, Novello S, Rosell R, Belani CP, Atkins JN, Gillenwater HH, Tye L, Chao R, Socinski MA. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non- small cell lung cancer (NSCLC): results from a phase II study [abstract]. ASCO Meeting Abstracts 2007;25:7542.
87. Reck M, Frickhofen N, Gatzemeier U, Fuhr H, Lanzalone S, Lechuga MJ, Wang E, Chao R, Felip E. A phase 1 dose escalation study of sunitinib in combination with gemcitabine + cisplatin for advanced non-small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2007;25:18057.
88. Robert F, Sandler A, Schiller JH, Ilagan J, VerMeulen W, Harper K, Liu G, Tye L, Chao R, Traynor A. A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs) [abstract]. ASCO Meeting Abstracts 2007;25:3543.
89. Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jurgensmeier JM, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:3045-3054.
90. Lorusso PM, Heath E, Valdivieso M, Pilat M, Wozniak A, Gadgeel S, Shields A, Puchalski T, Ewesuedo R. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors [abstract]. ASCO Meeting Abstracts 2006;24:3034.
91. van Cruijsen H, Voest EE, van Herpen CML, Hoekman K, Witteveen PO, Punt CJA, Puchalski TA, Fernandes N, Koehler M, Giaccone G. Phase I clinical evaluation of AZD2171 in combination with gefitinib, in patients with advanced tumors [abstract]. ASCO Meeting Abstracts 2005;23:3030.
92. Laurie SA, Gauthierl, Arnold A, ShepherdFA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. JClin Oncol 2008;26:1871-1878.
93. Goss GD, Laurie S, Shepherd F, Leighl N, Chen E, Gauthier I, Reaume N, Feld R, Powers J, Seymour L. IND. 175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): a study of the NCIC Clinical Trials Group [abstract]. ASCO Meeting Abstracts 2007;25:7649.
94. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006;66:8715-8721.
95. Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberg M, Mulay M, Purdom M, Yan L, Herbst RS. Safety and pharmacokinet- ics of AMG 706 in patients with advanced solid tumors [abstract]. ASCO Meeting Abstracts 2006;23:3013.
96. Price TJ, Lipton L, Williams J, McGreivy J, McCoy S, Sun Y, Aguero- O'Neill B, Rosenthal MA. Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors [abstract]. ASCO Meeting Abstracts 2007;25:14005.
97. Blumenschein G Jr, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden, C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/ paclitaxel (CP) for the treatment of patients (pts) with advanced non- small cell lung cancer (NSCLC) [abstract]. ASCO Meeting Abstracts 2006;24:7119.
98. Crawford J, Burris H, Stephenson J Jr, Otterson G, Stein M, McGreivy J, Sun Y, Ingram M, Yang L, Schwartzberg LS. Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer [abstract]. ASCO Meeting Abstracts 2007;25:14057.
99. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
100. Schiller JH, Larson T, Ou SI, Limentani SA, Sandler AB, Vokes EE, Kim S, Liau KF, Bycott PW, Olszanski AJ. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial [abstract]. ASCO Meeting Abstracts 2007;25:7507.
101. Hurwitz H, Dowlati A, Savage S, Fernando N, Lasalvia S, Whitehead B, Suttle B, Collins D, Ho P, Pandite L. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors [abstract]. ASCO Meeting Abstracts 2005;23:3012.
102. Nikolinakos P, Altorki N, Guarino M, Tran H, Rajagopalan D, Swann S, Bordogna W, Ottesen L, Yankelevitz D, Heymach JV. Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preopera- tive treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer [abstract]. J Clin Oncol 2008;26:7568.
103. Wakelee HA, Adjei AA, Halsey J, Lensing JL, Dugay JD, Hanson LJ, Reid JM, Piens JR, Sikic BI. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM) [abstract]. ASCO Meeting Abstracts 2006;24:3044.
104. Wakelee H, Adjei AA, Keer H, Halsey J, Hanson L, Reid J, Hutchison S, Piens J, Lacy S, Sikic BI. A phase I dose-escalation and phar- macokinetic (PK) study of a novel multiple-targeted receptor tyro- sine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies [abstract]. ASCO Meeting Abstracts 2005;23: 3142.
105. Wakelee HA, Fehling JM, Molina JR, Lensing JL, Funke RP, Miles D, Sikic BI. A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM) [abstract]. ASCO Meeting Abstracts 2008; 26:3528
106. Miller VA, Wakelee HA, Lara PN, Cho J, Chowhan NM, Costa D, Vrindavanam N, Yanagihara R, Pennell N, Lynch TJ. Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial [abstract]. ASCO Meeting Abstracts 2008;26:8028.
107. Rizvi NA, Kris MG, Miller VA, Krug LM, Bekele S, Dowlati A, Rowland KM, Salgia R, Aggarwal S, Gadgeel M. Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: result from Phase 2 [abstract]. ASCO Meeting Abstracts 2008;26:8053.